Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

US-based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile (formerly Clostridium) Associated Diarrheal Isolates from 2013-2016.

Thorpe CM, McDermott LA, Tran MK, Chang J, Jenkins SG, Goldstein EJC, Patel R, Forbes BA, Johnson S, Gerding DN, Snydman DR.

Antimicrob Agents Chemother. 2019 May 13. pii: AAC.00391-19. doi: 10.1128/AAC.00391-19. [Epub ahead of print]

PMID:
31085514
2.

Current and future trends in clostridioides (clostridium) difficile infection management.

Khanna S, Gerding DN.

Anaerobe. 2019 May 1. pii: S1075-9964(19)30077-0. doi: 10.1016/j.anaerobe.2019.04.010. [Epub ahead of print] Review.

PMID:
31054313
3.

Treatment of Recurrent Clostridium difficile Infection.

Johnson S, Gerding DN.

JAMA. 2019 Feb 5;321(5):512-513. doi: 10.1001/jama.2018.18993. No abstract available.

PMID:
30721288
4.

Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.

Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH.

Lancet Infect Dis. 2019 Mar;19(3):265-274. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29.

PMID:
30709665
5.

Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection with Greater Severity and Higher Recurrence Rates.

Guh AY, Hatfield KM, Winston LG, Martin B, Johnston H, Brousseau G, Farley MM, Wilson L, Perlmutter R, Phipps EC, Dumyati GK, Nelson D, Hatwar T, Kainer MA, Paulick AL, Karlsson M, Gerding DN, McDonald LC.

Clin Infect Dis. 2019 Jan 7. doi: 10.1093/cid/ciz009. [Epub ahead of print]

PMID:
30615074
6.

Non-toxigenic Clostridioides (Formerly Clostridium) difficile for Prevention of C. difficile Infection: From Bench to Bedside Back to Bench and Back to Bedside.

Gerding DN, Sambol SP, Johnson S.

Front Microbiol. 2018 Jul 26;9:1700. doi: 10.3389/fmicb.2018.01700. eCollection 2018. Review.

7.

Reply to Million et al.

Dubberke ER, Blount K, Gerding DN.

Clin Infect Dis. 2018 Nov 13;67(11):1799-1800. doi: 10.1093/cid/ciy460. No abstract available.

PMID:
30084881
8.

Bezlotoxumab.

Johnson S, Gerding DN.

Clin Infect Dis. 2019 Feb 1;68(4):699-704. doi: 10.1093/cid/ciy577.

PMID:
30020417
9.

Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strains.

Kociolek LK, Perdue ER, Fawley WN, Wilcox MH, Gerding DN, Johnson S.

Anaerobe. 2018 Dec;54:1-7. doi: 10.1016/j.anaerobe.2018.07.004. Epub 2018 Aug 3.

PMID:
30009944
10.

Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015.

Cheknis A, Johnson S, Chesnel L, Petrella L, Sambol S, Dale SE, Nary J, Sears P, Citron DM, Goldstein EJC, Gerding DN.

Anaerobe. 2018 Oct;53:38-42. doi: 10.1016/j.anaerobe.2018.05.009. Epub 2018 May 26.

PMID:
29886050
11.

Reply to Fabre et al.

McDonald LC, Johnson S, Bakken JS, Garey KW, Kelly C, Gerding DN.

Clin Infect Dis. 2018 Nov 28;67(12):1958-1959. doi: 10.1093/cid/ciy475. No abstract available.

PMID:
29860268
12.

Transmission of Clostridium difficile from asymptomatically colonized or infected long-term care facility residents.

Donskey CJ, Sunkesula VCK, Stone ND, Gould CV, McDonald LC, Samore M, Mayer J, Pacheco SM, Jencson AL, Sambol SP, Petrella LA, Gulvik CA, Gerding DN.

Infect Control Hosp Epidemiol. 2018 Aug;39(8):909-916. doi: 10.1017/ice.2018.106. Epub 2018 May 31.

PMID:
29848392
13.

Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study.

Guh AY, Adkins SH, Li Q, Bulens SN, Farley MM, Smith Z, Holzbauer SM, Whitten T, Phipps EC, Hancock EB, Dumyati G, Concannon C, Kainer MA, Rue B, Lyons C, Olson DM, Wilson L, Perlmutter R, Winston LG, Parker E, Bamberg W, Beldavs ZG, Ocampo V, Karlsson M, Gerding DN, McDonald LC.

Open Forum Infect Dis. 2017 Oct 26;4(4):ofx171. doi: 10.1093/ofid/ofx171. eCollection 2017 Fall.

14.

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.

Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN.

Clin Infect Dis. 2018 Sep 28;67(8):1198-1204. doi: 10.1093/cid/ciy259.

PMID:
29617739
15.

Reply to Collins and Riley.

McDonald LC, Gerding DN, Johnson S.

Clin Infect Dis. 2018 Oct 30;67(10):1640. doi: 10.1093/cid/ciy251. No abstract available.

PMID:
29590312
16.

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH.

Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149.

PMID:
29562266
17.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.

Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB.

Clin Infect Dis. 2018 Aug 16;67(5):649-656. doi: 10.1093/cid/ciy171.

18.

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH.

Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. doi: 10.1093/cid/cix1085.

19.

Research Agenda for Microbiome Based Research for Multidrug-resistant Organism Prevention in the Veterans Health Administration System.

Kates AE, Tischendorf JS, Schweizer M, Herwaldt L, Samore M, Dukes KC, Gerding DN, Diekema DJ, Safdar N.

Infect Control Hosp Epidemiol. 2018 Feb;39(2):202-209. doi: 10.1017/ice.2017.311. No abstract available.

PMID:
29417924
20.

Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106.

Kociolek LK, Gerding DN, Hecht DW, Ozer EA.

Microbes Infect. 2018 Apr;20(4):245-253. doi: 10.1016/j.micinf.2018.01.004. Epub 2018 Jan 31.

21.

Clostridium difficile Whole Genome Sequencing Reveals Limited Transmission Among Symptomatic Children: A Single-Center Analysis.

Kociolek LK, Gerding DN, Espinosa RO, Patel SJ, Shulman ST, Ozer EA.

Clin Infect Dis. 2018 Jul 2;67(2):229-234. doi: 10.1093/cid/ciy060.

PMID:
29370348
22.

Whole-genome analysis reveals the evolution and transmission of an MDR DH/NAP11/106 Clostridium difficile clone in a paediatric hospital.

Kociolek LK, Ozer EA, Gerding DN, Hecht DW, Patel SJ, Hauser AR.

J Antimicrob Chemother. 2018 May 1;73(5):1222-1229. doi: 10.1093/jac/dkx523.

23.

Trends in incidence of long-term-care facility onset Clostridium difficile infections in 10 US geographic locations during 2011-2015.

Guh AY, Mu Y, Baggs J, Winston LG, Bamberg W, Lyons C, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Beldavs ZG, Kainer MA, Karlsson M, Gerding DN, Dumyati G.

Am J Infect Control. 2018 Jul;46(7):840-842. doi: 10.1016/j.ajic.2017.11.026. Epub 2018 Jan 9.

PMID:
29329918
24.

Is pulsed dosing the answer to treatment of Clostridium difficile infection?

Gerding DN.

Lancet Infect Dis. 2018 Mar;18(3):231-233. doi: 10.1016/S1473-3099(17)30750-8. Epub 2017 Dec 19. No abstract available.

PMID:
29273270
25.

The Impact of Recurrent Clostridium difficile Infection on Patients' Prevention Behaviors.

Weaver FM, Trick WE, Evans CT, Lin MY, Adams W, Pho MT, Bleasdale SC, Mullane KM, Johnson S, Sikka MK, Peterson LR, Solomonides AE, Gerding DN.

Infect Control Hosp Epidemiol. 2017 Nov;38(11):1351-1357. doi: 10.1017/ice.2017.208. Epub 2017 Sep 26.

PMID:
28946934
26.

Complete Genome Sequence of Clostridioides difficile Epidemic Strain DH/NAP11/106/ST-42, Isolated from Stool from a Pediatric Patient with Diarrhea.

Ozer EA, Hauser AR, Gerding DN, Espinosa RO, Hecht DW, Kociolek LK.

Genome Announc. 2017 Sep 21;5(38). pii: e00923-17. doi: 10.1128/genomeA.00923-17.

27.

The Challenging Conundrum of Diagnosing and Managing Clostridium difficile Infection.

Gerding DN, Johnson S.

Mayo Clin Proc Innov Qual Outcomes. 2017 Jun 9;1(1):5-7. doi: 10.1016/j.mayocpiqo.2017.05.008. eCollection 2017 Jul. No abstract available.

28.

Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection.

Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN, Johnson S.

Clin Infect Dis. 2017 Oct 15;65(8):1396-1399. doi: 10.1093/cid/cix529.

PMID:
28591789
29.

Editorial: Making Fecal Microbiota Transplantation Easier to Swallow: Freeze-Dried Preparation for Recurrent Clostridium difficile Infections.

Youngster I, Gerding DN.

Am J Gastroenterol. 2017 Jun;112(6):948-950. doi: 10.1038/ajg.2017.91.

PMID:
28572645
30.

Correction for Cairns et al., "Comparative Genome Analysis and Global Phylogeny of the Toxin Variant Clostridium difficile PCR Ribotype 017 Reveals the Evolution of Two Independent Sublineages".

Cairns MD, Preston MD, Hall CL, Gerding DN, Hawkey PM, Kato H, Kim H, Kuijper EJ, Lawley TD, Pituch H, Reid S, Kullin B, Riley TV, Solomon K, Tsai PJ, Weese JS, Stabler RA, Wren BW.

J Clin Microbiol. 2017 Jun;55(6):1971. doi: 10.1128/JCM.00487-17. No abstract available.

31.

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.

Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFy study group.

Lancet Infect Dis. 2017 Jul;17(7):735-744. doi: 10.1016/S1473-3099(17)30235-9. Epub 2017 Apr 28.

32.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators.

N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.

33.

Comparative Genome Analysis and Global Phylogeny of the Toxin Variant Clostridium difficile PCR Ribotype 017 Reveals the Evolution of Two Independent Sublineages.

Cairns MD, Preston MD, Hall CL, Gerding DN, Hawkey PM, Kato H, Kim H, Kuijper EJ, Lawley TD, Pituch H, Reid S, Kullin B, Riley TV, Solomon K, Tsai PJ, Weese JS, Stabler RA, Wren BW.

J Clin Microbiol. 2017 Mar;55(3):865-876. doi: 10.1128/JCM.01296-16. Epub 2016 Dec 28. Erratum in: J Clin Microbiol. 2017 Jun;55(6):1971.

34.

Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection.

Johnson S, Gerding DN.

Clin Infect Dis. 2017 Feb 1;64(3):272-274. doi: 10.1093/cid/ciw735. Epub 2016 Nov 9. No abstract available.

PMID:
28011611
35.

Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection.

Dubberke ER, Mullane KM, Gerding DN, Lee CH, Louie TJ, Guthertz H, Jones C.

Open Forum Infect Dis. 2016 Jun 20;3(3):ofw133. eCollection 2016 Sep.

36.

Restriction Endonuclease Analysis Typing of Clostridium difficile Isolates.

Sambol SP, Johnson S, Gerding DN.

Methods Mol Biol. 2016;1476:1-13. doi: 10.1007/978-1-4939-6361-4_1.

PMID:
27507329
37.

Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.

Kociolek LK, Gerding DN, Osmolski JR, Patel SJ, Snydman DR, McDermott LA, Hecht DW.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4896-900. doi: 10.1128/AAC.00714-16. Print 2016 Aug.

38.

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases.

Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerding DN, Saeed MJ, Mahé C, Dubberke ER.

BMC Infect Dis. 2016 Apr 22;16:177. doi: 10.1186/s12879-016-1501-7.

39.

Breakthroughs in the treatment and prevention of Clostridium difficile infection.

Kociolek LK, Gerding DN.

Nat Rev Gastroenterol Hepatol. 2016 Mar;13(3):150-60. doi: 10.1038/nrgastro.2015.220. Epub 2016 Feb 10. Review.

PMID:
26860266
40.

Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis.

Dubberke ER, Olsen MA, Stwalley D, Kelly CP, Gerding DN, Young-Xu Y, Mahé C.

PLoS One. 2016 Feb 9;11(2):e0146822. doi: 10.1371/journal.pone.0146822. eCollection 2016.

41.

Burden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes.

Hunter JC, Mu Y, Dumyati GK, Farley MM, Winston LG, Johnston HL, Meek JI, Perlmutter R, Holzbauer SM, Beldavs ZG, Phipps EC, Dunn JR, Cohen JA, Avillan J, Stone ND, Gerding DN, McDonald LC, Lessa FC.

Open Forum Infect Dis. 2016 Jan 18;3(1):ofv196. doi: 10.1093/ofid/ofv196. eCollection 2016 Jan.

42.

Diagnosis and Treatment of Clostridium difficile Infection (CDI).

Gerding DN, File TM Jr, McDonald LC.

Infect Dis Clin Pract (Baltim Md). 2016 Jan;24(1):3-10. doi: 10.1097/IPC.0000000000000350.

43.

Editorial Commentary: Whole-Genome Sequencing of Clostridium difficile: Exquisitely Sensitive but Not Yet Optimally Applied.

Gerding DN.

Clin Infect Dis. 2016 Mar 15;62(6):753-4. doi: 10.1093/cid/civ1037. Epub 2015 Dec 18. No abstract available.

PMID:
26683316
44.

Concomitant Medical Conditions and Therapies Preclude Accurate Classification of Children With Severe or Severe Complicated Clostridium difficile Infection.

Kociolek LK, Patel SJ, Shulman ST, Gerding DN.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e139-42. doi: 10.1093/jpids/piu121. Epub 2014 Dec 29.

PMID:
26582882
45.

Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.

Wieczorkiewicz JT, Lopansri BK, Cheknis A, Osmolski JR, Hecht DW, Gerding DN, Johnson S.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):418-23. doi: 10.1128/AAC.01820-15. Print 2016 Jan.

46.

Clinical and Microbiologic Assessment of Cases of Pediatric Community-associated Clostridium difficile Infection Reveals Opportunities for Improved Testing Decisions.

Kociolek LK, Patel SJ, Zheng X, Todd KM, Shulman ST, Gerding DN.

Pediatr Infect Dis J. 2016 Feb;35(2):157-61. doi: 10.1097/INF.0000000000000954.

PMID:
26517329
47.

Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027.

Kociolek LK, Gerding DN.

J Clin Microbiol. 2016 Jan;54(1):19-24. doi: 10.1128/JCM.02340-15. Epub 2015 Oct 28. Review.

48.

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.

Gerding DN, Hecht DW, Louie T, Nord CE, Talbot GH, Cornely OA, Buitrago M, Best E, Sambol S, Osmolski JR, Kracker H, Locher HH, Charef P, Wilcox M.

J Antimicrob Chemother. 2016 Jan;71(1):213-9. doi: 10.1093/jac/dkv300. Epub 2015 Oct 3.

49.

Analysis of Bacterial Communities during Clostridium difficile Infection in the Mouse.

Semenyuk EG, Poroyko VA, Johnston PF, Jones SE, Knight KL, Gerding DN, Driks A.

Infect Immun. 2015 Nov;83(11):4383-91. doi: 10.1128/IAI.00145-15. Epub 2015 Aug 31.

50.

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.

Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6266-73. doi: 10.1128/AAC.00504-15. Epub 2015 Jul 27.

Supplemental Content

Loading ...
Support Center